Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis.

Maier M, Welt T, Wirth F, Montrasio F, Preisig D, McAfoose J, Vieira FG, Kulic L, Späni C, Stehle T, Perrin S, Weber M, Hock C, Nitsch RM, Grimm J.

Sci Transl Med. 2018 Dec 5;10(470). pii: eaah3924. doi: 10.1126/scitranslmed.aah3924.

PMID:
30518612
2.

Sex-related responses after traumatic brain injury: Considerations for preclinical modeling.

Späni CB, Braun DJ, Van Eldik LJ.

Front Neuroendocrinol. 2018 Jul;50:52-66. doi: 10.1016/j.yfrne.2018.03.006. Epub 2018 May 18. Review.

PMID:
29753798
3.

Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes.

Zhou Z, Bachstetter AD, Späni CB, Roy SM, Watterson DM, Van Eldik LJ.

J Neuroinflammation. 2017 Apr 5;14(1):75. doi: 10.1186/s12974-017-0845-2.

4.

Genetic ablation of the p66Shc adaptor protein reverses cognitive deficits and improves mitochondrial function in an APP transgenic mouse model of Alzheimer's disease.

Derungs R, Camici GG, Spescha RD, Welt T, Tackenberg C, Späni C, Wirth F, Grimm A, Eckert A, Nitsch RM, Kulic L.

Mol Psychiatry. 2017 Apr;22(4):605-614. doi: 10.1038/mp.2016.112. Epub 2016 Jul 19.

PMID:
27431297
5.

High-speed video gait analysis reveals early and characteristic locomotor phenotypes in mouse models of neurodegenerative movement disorders.

Preisig DF, Kulic L, Krüger M, Wirth F, McAfoose J, Späni C, Gantenbein P, Derungs R, Nitsch RM, Welt T.

Behav Brain Res. 2016 Sep 15;311:340-353. doi: 10.1016/j.bbr.2016.04.044. Epub 2016 May 24.

PMID:
27233823
6.

T-cell brain infiltration and immature antigen-presenting cells in transgenic models of Alzheimer's disease-like cerebral amyloidosis.

Ferretti MT, Merlini M, Späni C, Gericke C, Schweizer N, Enzmann G, Engelhardt B, Kulic L, Suter T, Nitsch RM.

Brain Behav Immun. 2016 May;54:211-225. doi: 10.1016/j.bbi.2016.02.009. Epub 2016 Feb 9.

7.

Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer's disease lacking functional B and T cells.

Späni C, Suter T, Derungs R, Ferretti MT, Welt T, Wirth F, Gericke C, Nitsch RM, Kulic L.

Acta Neuropathol Commun. 2015 Nov 11;3:71. doi: 10.1186/s40478-015-0251-x.

8.

Acute Effects of Muscarinic M1 Receptor Modulation on AβPP Metabolism and Amyloid-β Levels in vivo: A Microdialysis Study.

Welt T, Kulic L, Hoey SE, McAfoose J, Späni C, Chadha AS, Fisher A, Nitsch RM.

J Alzheimers Dis. 2015;46(4):971-82. doi: 10.3233/JAD-150152.

PMID:
25881909
9.

Amyloid-β peptide-specific DARPins as a novel class of potential therapeutics for Alzheimer disease.

Hanenberg M, McAfoose J, Kulic L, Welt T, Wirth F, Parizek P, Strobel L, Cattepoel S, Späni C, Derungs R, Maier M, Plückthun A, Nitsch RM.

J Biol Chem. 2014 Sep 26;289(39):27080-9. doi: 10.1074/jbc.M114.564013. Epub 2014 Aug 12.

10.

Accurate and Reliable Gait Cycle Detection in Parkinson's Disease.

Hundza SR, Hook WR, Harris CR, Mahajan SV, Leslie PA, Spani CA, Spalteholz LG, Birch BJ, Commandeur DT, Livingston NJ.

IEEE Trans Neural Syst Rehabil Eng. 2014 Jan;22(1):127-37. doi: 10.1109/TNSRE.2013.2282080. Epub 2013 Oct 22.

PMID:
24158491
11.

Early accumulation of intracellular fibrillar oligomers and late congophilic amyloid angiopathy in mice expressing the Osaka intra-Aβ APP mutation.

Kulic L, McAfoose J, Welt T, Tackenberg C, Späni C, Wirth F, Finder V, Konietzko U, Giese M, Eckert A, Noriaki K, Shimizu T, Murakami K, Irie K, Rasool S, Glabe C, Hock C, Nitsch RM.

Transl Psychiatry. 2012 Nov 13;2:e183. doi: 10.1038/tp.2012.109.

Supplemental Content

Support Center